Plasmodium deoxyribonucleic acid (Plasmodium DNA)

Plasmodium deoxyribonucleic acid (DNA) serves as the fundamental genetic material for the protozoan parasites of the genus Plasmodium, which are responsible for malaria (WHO, 2023). This DNA encodes the instructions for the parasite's development, metabolism, and evasion of the host immune system across its multi-stage life cycle (NCBI, 2022). In the context of pharmacology, Plasmodium DNA is a target for various small-molecule drugs that disrupt its structural and functional integrity. These agents typically act by intercalating into the DNA helix or binding to the minor groove, which effectively halts DNA replication and RNA synthesis (PubMed, 2021). While effective at killing the parasite, the therapeutic utility of DNA-targeting agents is often limited by the risk of cross-reactivity with host DNA, necessitating careful drug design to achieve parasite-specific toxicity (PubChem, 2023). Monitoring parasite DNA levels in the blood is also a critical tool for diagnosing infection and assessing the efficacy of antimalarial treatments (Journal of Infectious Diseases, 2021).

Other names

Malarial DNAPlasmodium falciparum DNAParasite DNA

Inhibition of DNA replication and transcription through intercalation or minor groove binding (PubMed, 2021; NCBI, 2023).